MA53118A - Alcoxy pyrazoles en tant qu'activateurs de la guanylate cyclase soluble - Google Patents
Alcoxy pyrazoles en tant qu'activateurs de la guanylate cyclase solubleInfo
- Publication number
- MA53118A MA53118A MA053118A MA53118A MA53118A MA 53118 A MA53118 A MA 53118A MA 053118 A MA053118 A MA 053118A MA 53118 A MA53118 A MA 53118A MA 53118 A MA53118 A MA 53118A
- Authority
- MA
- Morocco
- Prior art keywords
- alcoxy
- pyrazoles
- guanylate cyclase
- soluble guanylate
- cyclase activators
- Prior art date
Links
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 title 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 title 1
- 239000003119 guanylate cyclase activator Substances 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696887P | 2018-07-12 | 2018-07-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA53118A true MA53118A (fr) | 2021-05-19 |
Family
ID=67314737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA053118A MA53118A (fr) | 2018-07-12 | 2019-07-09 | Alcoxy pyrazoles en tant qu'activateurs de la guanylate cyclase soluble |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11690848B2 (enExample) |
| EP (1) | EP3820470B1 (enExample) |
| JP (2) | JP2021530488A (enExample) |
| KR (1) | KR20210032443A (enExample) |
| CN (1) | CN112384214A (enExample) |
| AU (1) | AU2019301887A1 (enExample) |
| BR (1) | BR112020025670A2 (enExample) |
| CA (1) | CA3103727A1 (enExample) |
| CL (1) | CL2021000023A1 (enExample) |
| EA (1) | EA202190193A1 (enExample) |
| MA (1) | MA53118A (enExample) |
| MX (1) | MX2021000405A (enExample) |
| PH (1) | PH12021550075A1 (enExample) |
| WO (1) | WO2020011804A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4496571A1 (en) * | 2022-03-21 | 2025-01-29 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators for treating portal hypertension |
| CN120225203A (zh) * | 2022-11-04 | 2025-06-27 | 勃林格殷格翰国际有限公司 | 用于治疗系统性硬化症的可溶性鸟苷酸环化酶活化剂 |
| WO2024123847A1 (en) | 2022-12-09 | 2024-06-13 | Boehringer Ingelheim International Gmbh | Solid forms of a sgc activator |
| CN121620369A (zh) * | 2023-08-16 | 2026-03-06 | 勃林格殷格翰国际有限公司 | 用于治疗临床显著门静脉高压和失代偿期肝硬化的可溶性鸟苷酸环化酶激活剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20191755T1 (hr) | 2012-09-07 | 2019-12-27 | Boehringer Ingelheim International Gmbh | Alkoksipirazoli kao aktivatori topljive gvanilat ciklaze |
| AU2017216429B2 (en) * | 2016-02-01 | 2022-10-06 | Cyclerion Therapeutics, Inc. | Use of sGC stimulators for the treatment of Nonalcoholic Steatohepatitis (NASH) |
| EP3458063A4 (en) * | 2016-05-18 | 2020-02-26 | Merck Sharp & Dohme Corp. | METHOD FOR USE OF TRIAZOLO-PYRAZINYL-SOLUBLE GUANYLATE CYCLASE ACTIVATORS IN FIBROTIC DISEASES |
-
2019
- 2019-07-09 WO PCT/EP2019/068448 patent/WO2020011804A1/en not_active Ceased
- 2019-07-09 JP JP2021500613A patent/JP2021530488A/ja active Pending
- 2019-07-09 BR BR112020025670-6A patent/BR112020025670A2/pt not_active IP Right Cessation
- 2019-07-09 AU AU2019301887A patent/AU2019301887A1/en not_active Abandoned
- 2019-07-09 KR KR1020217004281A patent/KR20210032443A/ko not_active Ceased
- 2019-07-09 US US17/258,759 patent/US11690848B2/en active Active
- 2019-07-09 EP EP19740509.5A patent/EP3820470B1/en active Active
- 2019-07-09 EA EA202190193A patent/EA202190193A1/ru unknown
- 2019-07-09 CN CN201980045881.XA patent/CN112384214A/zh active Pending
- 2019-07-09 CA CA3103727A patent/CA3103727A1/en active Pending
- 2019-07-09 MA MA053118A patent/MA53118A/fr unknown
- 2019-07-09 MX MX2021000405A patent/MX2021000405A/es unknown
-
2021
- 2021-01-06 CL CL2021000023A patent/CL2021000023A1/es unknown
- 2021-01-12 PH PH12021550075A patent/PH12021550075A1/en unknown
-
2024
- 2024-03-27 JP JP2024052193A patent/JP2024095711A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024095711A (ja) | 2024-07-10 |
| JP2021530488A (ja) | 2021-11-11 |
| PH12021550075A1 (en) | 2021-09-20 |
| AU2019301887A1 (en) | 2021-01-07 |
| EP3820470A1 (en) | 2021-05-19 |
| CA3103727A1 (en) | 2020-01-16 |
| WO2020011804A1 (en) | 2020-01-16 |
| BR112020025670A2 (pt) | 2021-03-16 |
| CN112384214A (zh) | 2021-02-19 |
| EP3820470B1 (en) | 2024-09-11 |
| KR20210032443A (ko) | 2021-03-24 |
| US20210121473A1 (en) | 2021-04-29 |
| US11690848B2 (en) | 2023-07-04 |
| EA202190193A1 (ru) | 2021-06-16 |
| CL2021000023A1 (es) | 2021-06-11 |
| MX2021000405A (es) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3883570A4 (en) | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | |
| EP3621624A4 (en) | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| MA53377A (fr) | Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2 | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| EP3953331A4 (en) | PYRAZOLESULFONAMIDES AS ANTITUMORS | |
| MA52754A (fr) | Composés hétérocycliques tricycliques en tant qu'activateurs de sting | |
| EP3755311A4 (en) | INDANAMINE AS PD-L1 ANTAGONISTS | |
| MA53118A (fr) | Alcoxy pyrazoles en tant qu'activateurs de la guanylate cyclase soluble | |
| EP3344644A4 (en) | CYCLIC DI NUCLEOTIDE COMPOUNDS AS STING AGONISTS | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| EP4013496A4 (en) | THROMBOSOMES AS AN AGENT FOR REMOVING THE THROMBOCYTE AGGREGATION-INHIBITING EFFECT | |
| FR25C1047I1 (fr) | Aminopyrazoles en tant qu'inhibiteurs sélectifs de janus kinase | |
| MA46745A (fr) | Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v | |
| MA45153A (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
| EP3656769A4 (en) | ARYL-PHOSPHORUS-OXYGEN COMPOUND AS EGFR KINASE INHIBITOR | |
| EP3861343A4 (en) | ULTRA-BRIGHT FLUORESCENT NANOSTRUCTURES AS UNIVERSAL AMPLIFIERS | |
| MA54939A (fr) | Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2 | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
| EP3733671A4 (en) | AMINOFLUOROPERIDINE DERIVATIVES AS KINAS INHIBITOR | |
| MA51431A (fr) | Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase | |
| MA46824A (fr) | Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj | |
| MA50013A (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton |